Tag: Psychiatrist

  • šŸ’„Ā Time to Rethink Valproate in Acute Mania

    Valproate continues to be overvalued in the treatment of acute mania—and it doesn’t work as well as many assume.

    Part of the problem? A single overhyped study, cleverly marketed by the pharmaceutical company, has shaped decades of prescribing habits and continues to be taught to psychiatry residents as gold-standard evidence.

    But the data tells a different story.
    The BALANCE study (British study of Lithium +/āˆ’ Valproate) showed no significant long-term benefit to adding valproate to lithium over a 2-year period in bipolar disorder.

    It’s time we stop relying on outdated assumptions and start practicing based on robust, long-term outcomes—not industry narratives.

    šŸ“š Evidence over tradition.
    🧠 Teach residents the full picture.
    šŸ’Š Prescribe with precision.

  • Is olanzapine overrated for acute mania?

    🧠 Olanzapine has built a reputation as a heavy-hitter for treating acute manic episodes—but the data tells a more modest story.

    In one key study comparing olanzapine vs. placebo over 3 weeks:

    • Response rate: 55% (olanzapine) vs. 30% (placebo)
    • Remission rate: 18% (olanzapine) vs. 7% (placebo)

    That’s a 25% absolute difference in response and just an 11% difference in remission—not exactly blockbuster results.

    This doesn’t mean olanzapine has no role in mania treatment. But it’s time to recalibrate our expectations and remain clear-eyed about what the data shows.

    šŸ’Š Efficacy matters. So does the narrative we build around our tools.

  • Rapid cycling ≠ lithium failure

    There’s a persistent myth in psychiatry thatĀ lithium doesn’t workĀ for bipolar disorder with rapid cycling.

    🧠 But here’s the truth:
    Multiple literature reviews show lithium performs just as well as other antimanic agents in rapid cyclers. The issue isn’t lithium—it’s that rapid cycling is simply harder to treat overall.

    Let’s stop excluding one of our most effective mood stabilizers based on outdated or anecdotal thinking. Patients with rapid cycling deserve full access to evidence-based treatment options—including lithium.

  • New Mechanism, Promising Results: Novel PDE10A Inhibitor for Acute Schizophrenia

    New Mechanism, Promising Results: Novel PDE10A Inhibitor for Acute Schizophrenia

    A novel PDE10A inhibitor just showed safety and efficacy in a large Phase 2 trial for acute schizophrenia. šŸ‘

    šŸ“Œ PDE10A inhibitors represent a non-dopaminergic approach—targeting phosphodiesterase 10A to modulate both D1 and D2 pathways indirectly. This could be a game-changer for patients who don’t respond to or can’t tolerate traditional D2 blockers.

    šŸ” The trial demonstrated:
    āœ… Significant reduction in PANSS total scores
    āœ… Favorable side effect profile (no EPS or prolactin elevation)
    āœ… Oral formulation, once daily

    This reinforces the urgent need to diversify our treatment mechanisms beyond dopamine antagonism. As treatment-resistant schizophrenia remains a major challenge, we’ll take all the innovation we can get.

    🧠 Stay tuned—PDE10A could join the ranks of TAAR1 agonists and muscarinic agents in reshaping how we treat serious mental illness.

  • The Benzo Balance: Short-Term Help, Long-Term Plan

    The Benzo Balance: Short-Term Help, Long-Term Plan

    1.Ā Clarity and upfront expectations reduce long-term problems

    ā€œI’m prescribing this for 4–6 weeks. After that, we taper.ā€
    We give the patient a clear framework and prevent long-term dependency from becoming the default trajectory. It builds trust while still honoring clinical caution. Patients usually appreciate this transparency.

    2.Ā Dose low. Time-limit strictly

    This really is the heart of rational benzo use. When used short-term for acute anxiety, panic, alcohol withdrawal, catatonia, etc., theyĀ canĀ be valuable. But once we drift into long-term, open-ended prescribing, the benefits decline and risks (dependence, cognitive impairment, falls, tolerance) mount.

    3.Ā Cold-turkey tapers can be dangerous

    ā€œSome well-meaning physician decides to pull someone off benzodiazepines in 2 weeksā€¦ā€
    And suddenly the patient is in crisis — not because the drug was inherently evil, but because the withdrawal was mishandled. Abrupt tapers, especially in someone on high doses or for years, can trigger rebound anxiety, insomnia, panic, even seizures or suicidality.

    4.Ā We need to hold both truths at once

    • Benzos are not long-term solutions for anxiety.
    • But abrupt discontinuation without a tailored plan is often worse than the original problem.

    It’s not a complex principle, but it takes nuanced execution. You’re advocating for that middle path: compassionate, firm, individualized.

  • Dexmedetomidine for Acute Agitation in Bipolar and Schizophrenia: Worth the Hype?

    I recently received a great question about the use of dexmedetomidine for acute agitation. With its recent FDA approval for agitation associated with bipolar disorder and schizophrenia, it’s only natural to wonder: is this the new go-to treatment, or just another overhyped medication?

    Let’s start with the obvious. New medications almost always come with a hefty price tag. That cost is only justifiable if they outperform existing options in either efficacy or safety—and in this case, dexmedetomidine falls short on both fronts.

    Current data suggest it does not provide superior outcomes when compared to existing, well-established medications like lorazepam, haloperidol, or olanzapine. And it brings along its own baggage: bradycardia, hypotension, and sedation-related complications that can be clinically significant, especially in medically complex patients.

    When you combine the high cost with a safety profile that raises some red flags—and no clear advantage in efficacy—it becomes hard to justify widespread use.

    For now, I’d place dexmedetomidine in the ā€œhypeā€ category. We already have effective, affordable options with strong track records in managing acute agitation. Until further data prove otherwise, there’s little reason to switch.

  • Understanding Social Anxiety Disorder: Key Insights and Treatments

    Understanding Social Anxiety Disorder: Key Insights and Treatments

    What if your biggest fear was simply being seen?
    For millions living withĀ Social Anxiety Disorder (SAD), everyday interactions—like answering a question in class or speaking up at work—can feel terrifying. Despite being one of the most prevalent and impairing anxiety conditions, SAD remains widely under-recognized.

    šŸ“Š Up to 8.4% of people meet criteria for SAD in a given year, yet only 20–40% recover after 20 years without treatment (Ruscio et al., 2008). Median age of onset? Just 13 years old.

    šŸ‘¤Ā Case Vignette: When Fear Takes Over

    At 15, ā€œJennaā€ stopped raising her hand in class—not because she didn’t know the answers, but because she was terrified of being laughed at. By college, she avoided presentations, skipped networking events, and turned down internships. Her friends thought she was shy. One professor suggested depression. But underneath was a paralyzing fear of judgment: classicĀ Social Anxiety Disorder.

    šŸ¤ What Is Social Anxiety Disorder?

    SAD is more than introversion or shyness. It’s a persistent, intense fear of being judged, embarrassed, or negatively evaluated in social or performance situations. This fear leads toĀ avoidance behaviorsĀ that impair social, academic, and occupational functioning.

    āš ļø Why Is It So Often Missed?

    SAD is frequently overshadowed by overlapping symptoms seen in:

    • Major Depressive DisorderĀ (social withdrawal, low self-esteem)
    • Generalized Anxiety DisorderĀ (excessive worry)
    • Avoidant Personality DisorderĀ (longstanding social inhibition)
    • Body Dysmorphic DisorderĀ (fear of negative evaluation tied to appearance)

    Because of this diagnostic overlap, many individuals go undiagnosed—or misdiagnosed—for years.

    🧠 Clinical Considerations

    1. SAD Is Not “Just Shyness”

    Shyness is a personality trait; SAD is a clinical condition. The difference lies in impairment: SAD interferes with daily life, relationships, academic goals, and career opportunities.

    2. Early Onset, Long Course

    Most individuals report symptoms starting in early adolescence. Without intervention, SAD often persists into adulthood and increases the risk of depressionsubstance use, and functional disability.

    3. Functional Impairment Is Significant

    SAD can lead to:

    • Academic underachievement
    • Avoidance of job interviews or public speaking
    • Social isolation
    • Delayed life milestones (e.g., dating, career advancement)

    4. Evidence-Based Treatments Exist

    🧠 Cognitive Behavioral Therapy (CBT):

    • Gold-standard psychotherapy
    • Targets negative thought patterns and avoidance behaviors
    • Often includes exposure exercises to feared situations
    • Group CBT is especially effective for SAD

    šŸ’Š Pharmacologic Options:

    • First-line: SSRIs (e.g., sertraline, paroxetine)
    • SNRIs: Like venlafaxine, also effective
    • Beta-blockers: May help withĀ performance-onlyĀ SAD (e.g., public speaking)
    • Benzodiazepines:Ā Not recommendedĀ due to dependence risks and avoidance reinforcement

    šŸ”„ Combined Therapy

    Some individuals benefit most from CBT + medication, particularly those with moderate-to-severe or treatment-resistant symptoms.

    šŸ“£ Call to Action

    Too many individuals live in silence with Social Anxiety Disorder. If you or someone you know avoids social situations due to fear of judgment, don’t ignore it. SAD is real. It’s common. And—most importantly—it’s treatable.

    šŸ‘‰ Talk to a mental health professional
    šŸ‘‰ Share this post to raise awareness
    šŸ‘‰ Start the conversation

  • šŸ“‰Ā Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of HopeĀ šŸ‡ŗšŸ‡ø

    šŸ“‰Ā Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of HopeĀ šŸ‡ŗšŸ‡ø

    šŸ“‰ Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of Hope šŸ‡ŗšŸ‡ø

    According to newly released CDC data, the U.S. experienced a nearly 27% decline in overdose deaths last year ā€” the first major drop in over five years. While the crisis is far from over, this marks a critical turning point and a reason for cautious optimism.

    Key contributors to this progress include:

    āœ… Expansion of harm reduction strategies

    āœ… Increased access to naloxone and medications for opioid use disorder

    āœ… Shifts in drug supply dynamics and targeted public health interventions

    As someone on the front lines caring for patients every day, I’ve witnessed firsthand the devastating toll of opioid addiction. I’ve lost patients to this crisis — and I’ve also seen close friends and family fight their way back from the brink. Their recovery wouldn’t have been possible without access to critical resources, especially life-saving medications and sustained support.

    This progress didn’t happen by chance — it’s the result of continued investment in prevention, treatment, and recovery. We cannot afford to lose momentum now. If anything, this is the moment to double down.

    Let’s keep the pressure on. Reach out to your representatives. Push for increased funding. Our collective commitment has brought us this far — now let’s go even further. Lives depend on it.

    Let’s build on this progress with compassion, science, and unwavering commitment.

  • Avoid Tianeptine: FDA Alerts Consumers to Risks

    Avoid Tianeptine: FDA Alerts Consumers to Risks

    The U.S. Food and Drug Administration (FDA) has issued a critical health warning about the growing availability of tianeptine, a dangerous, unapproved substance being sold as a dietary supplement under names like Zaza, Tianna Red, Pegasus, and others.

    Commonly referred to as ā€œgas station heroinā€, tianeptine mimics opioid-like effects and is being sold in convenience stores, gas stations, smoke shops, and online—posing serious health risks to the public.

    āš ļø Why This Matters:

    Tianeptine isĀ not approvedĀ for any medical use in the U.S. Despite this, it is widely marketed for supposed benefits like mood enhancement, anxiety relief, or cognitive boost. These claims areĀ not supported by clinical evidence, and the risks are significant.

    🩺 Serious Health Risks Associated With Tianeptine:

    āš ļø Death, particularly when combined with alcohol or other substances

    āš ļø Respiratory depression (slow or stopped breathing)

    āš ļø Seizures

    āš ļø Loss of consciousness

    āš ļø Confusion and agitation

    āš ļø Opioid-like withdrawal symptoms

    šŸ›‘ What You Can Do:

    Report adverse reactionsĀ to the FDA via MedWatch:Ā https://www.fda.gov/medwatch

    AvoidĀ any products labeled as containing tianeptine.

    Do not trustĀ unregulated supplements marketed for mental clarity or energy.

    šŸ“Œ Quick Summary:

    • Tianeptine = dangerous, unapproved opioid-like drug
    • Sold as a supplement under names likeĀ ZazaĀ orĀ Tianna Red
    • Linked toĀ seizures, coma, and death
    • Avoid these productsĀ and warn others
    • Report side effects to theĀ FDA MedWatch Program
  • The Importance of Distinguishing Suicidal Behaviors

    The Importance of Distinguishing Suicidal Behaviors

    This is the subject of a recent discussion I had with a colleague regarding the differences between a suicide attempt and a suicide gesture. Though these terms are sometimes used interchangeably in casual conversation or even in clinical documentation, they carry fundamentally different meanings—both in terms of patient risk and in how we, as clinicians, should respond.

    Our conversation emerged from a case involving a patient with borderline personality disorder who presented to the emergency department after ingesting a small quantity of over-the-counter medication. The intent was unclear. Was this a serious attempt to end her life? Or was it a gesture—an act of desperation without the intention to die, but rather to communicate emotional distress?

    The question is not academic. Our interpretation of the event determines our risk formulation, our documentation, our treatment planning, and even how we communicate with the patient and their support system. Yet, it is precisely in these gray areas that clinicians often struggle, and where outdated or stigmatizing language can do real harm.

    Defining the Terms: Clinical and Functional Differences

    suicide attempt refers to an act of self-harm with at least some intent to die. The degree of lethality may vary, but what distinguishes an attempt is that the individual believed the act could result in death and engaged in it with that goal in mind—even if ambivalence was present. The National Institute of Mental Health (NIMH) and the Columbia-Suicide Severity Rating Scale (C-SSRS) define this with some specificity: any potentially self-injurious behavior with non-zerointent to die, regardless of outcome.

    In contrast, a suicidal gesture is a behavior that mimics suicidal behavior or appears life-threatening but is typically not intended to be fatal. The function is often communicative or affect-regulating rather than aimed at death. Classic examples include superficial wrist-cutting, ingesting a sub-lethal dose of medication, or tying a noose but not tightening it. These acts often occur in interpersonal contexts and can be seen as efforts to signal pain, elicit help, or assert control in the face of perceived abandonment.

    Why the Distinction Matters

    It might be tempting to dismiss suicidal gestures as ā€œattention-seekingā€ or ā€œmanipulative,ā€ but this framing is both clinically dangerous and ethically fraught. Individuals who engage in gestures often experience intense psychological suffering, and repeated gestures are a well-established risk factor for future suicide attempts and completed suicide.

    From a risk assessment standpoint, gestures should be taken seriously, especially when they become part of a pattern. While the intent to die may not be present in a given gesture, intent can shift quickly, particularly in individuals with mood disorders, personality pathology, or under the influence of substances.

    From a treatment perspective, understanding the function of the behavior—whether it is to relieve affective tension, to communicate distress, or to punish oneself—is crucial to tailoring interventions. For instance, dialectical behavior therapy (DBT) explicitly targets self-harm and suicidal gestures as part of its hierarchy of treatment priorities, recognizing the urgency and potential danger of these behaviors even when lethality is low.

    Conclusion: Clarify, Don’t Categorize

    Ultimately, the conversation with my colleague reminded me that the real clinical challenge is not to label a behavior as a suicide attempt or a gesture, but to understand its meaning in the life of the patient. Both require empathy, structure, and a willingness to engage with complexity. Whether a patient wants to die or wants their suffering to be seen and acknowledged, both deserve serious clinical attention.

    By sharpening our definitions and approaching these behaviors with nuance, we can better serve patients in crisis and avoid the pitfalls of assumptions—especially in emotionally charged clinical environments like emergency rooms, inpatient units, or high-acuity outpatient settings.